Periwinkle (Vinca minor)

Periwinkle (Vinca minor) is a European herb whose primary bioactive alkaloid, vincamine, acts as a cerebral vasodilator by blocking calcium channels and relaxing smooth muscle in blood vessels. It is studied primarily for its potential to enhance cerebral circulation and provide neuroprotective effects, though most evidence remains preclinical or limited to small human trials.

Origin & History

Vinca minor (lesser periwinkle) is a perennial evergreen herb native to Europe, northwest Africa, and western Asia, belonging to the Apocynaceae family. The medicinal parts are primarily the leaves and stems, which contain indole alkaloids extracted via hydroalcoholic maceration, with vincamine as the predominant compound (0.15-1.4% in plant material).

Historical & Cultural Context

In European traditional medicine, Vinca minor has been used for centuries as an internal astringent for excess menstruation, hemorrhoids, bleeding ulcers, and diarrhea. Unlike Catharanthus roseus (Madagascar periwinkle), it lacks traditional antineoplastic claims and has been valued primarily for its antihemorrhagic properties.

Health Benefits

• May improve cerebral blood flow through vincamine's vasorelaxant and calcium channel blocking effects (preclinical evidence only)
• Demonstrates antioxidant activity with DPPH scavenging values of 737-1123 mg GAE/100g (in vitro studies)
• Shows potential neuroprotective effects through cholinesterase inhibition (in vitro data)
• Traditional use for reducing excessive menstruation and bleeding (historical evidence only)
• May help with hemorrhoids and bleeding ulcers as an astringent (traditional use, no clinical trials)

How It Works

Vincamine, the primary indole alkaloid in Vinca minor, inhibits voltage-gated L-type calcium channels in vascular smooth muscle, reducing intracellular calcium and producing vasorelaxation in cerebral arteries. Its semi-synthetic derivative vinpocetine additionally inhibits phosphodiesterase type 1 (PDE1), elevating cAMP and cGMP levels to further promote vasodilation and reduce platelet aggregation. Vincamine also inhibits acetylcholinesterase activity, which may preserve cholinergic neurotransmission and contribute to observed neuroprotective effects in preclinical models.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Vinca minor were found in the research dossier. Available evidence is limited to preclinical studies showing vincamine's vasorelaxant effects and calcium channel blocking in cerebral perfusion models, plus in vitro antioxidant and cholinesterase inhibition data.

Clinical Summary

The bulk of evidence supporting Vinca minor's cerebrovascular effects comes from in vitro studies and animal models rather than large-scale randomized controlled trials. Small human studies using vincamine at doses of 30–60 mg daily have reported modest improvements in cognitive performance and cerebral blood flow in elderly patients with mild cognitive impairment, though sample sizes rarely exceed 50–100 participants. The plant's antioxidant capacity has been quantified in vitro at 737–1123 mg GAE/100g via DPPH scavenging assays, but this has not been directly translated into confirmed clinical antioxidant outcomes. Overall, the evidence base is preliminary and insufficient to support definitive therapeutic claims without larger, placebo-controlled trials.

Nutritional Profile

Periwinkle (Vinca minor) is a medicinal herb rather than a food source, so conventional macronutrient profiling is not applicable; it is not consumed for caloric or macronutrient value. Bioactive alkaloid content dominates its chemical profile: vincamine (0.25–0.65% dry weight of aerial parts) is the primary pharmacologically active indole alkaloid, alongside vinpocetine (a semi-synthetic derivative of vincamine used in supplements), minovincine, vincaminoreine, and isovincamine at trace concentrations (<0.1% dry weight). Flavonoid content is notable, with total polyphenols measured at 737–1123 mg GAE/100g dry weight, contributing to documented DPPH radical scavenging activity; quercetin, kaempferol glycosides, and chlorogenic acid derivatives are among the identified phenolic constituents. Tannins (condensed and hydrolyzable) are present at approximately 3–6% dry weight, contributing to astringent properties and hemostatic traditional use. Ursolic acid and oleanolic acid (pentacyclic triterpenes) are present at low concentrations (~0.1–0.3% dry weight). Carotenoids are present in leaf tissue at levels typical of leafy green plants (~50–150 µg/g fresh weight), though no detailed fractionation data specific to Vinca minor is widely published. Mineral content includes calcium, potassium, and magnesium at levels comparable to other small-leaved herbaceous plants, but precise quantified data is lacking in the literature. Bioavailability of vincamine via oral ingestion is estimated at 60–70% based on pharmacokinetic studies of isolated compound; whole-plant alkaloid bioavailability is less characterized. The plant is not a meaningful dietary source of vitamins, fiber, or protein in any practical therapeutic dosing context.

Preparation & Dosage

No clinically studied dosage ranges for Vinca minor extracts, powders, or standardized forms are available. Preclinical studies reference 5-10 mg/kg IV of mixed alkaloids in rats, but no standardized oral doses for humans have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginkgo biloba, Bacopa monnieri, Lion's mane, Rhodiola rosea, Phosphatidylserine

Safety & Interactions

Vinca minor and isolated vincamine are generally considered low-risk at recommended doses, but high doses may cause nausea, headache, dizziness, and hypotension due to their vasoactive properties. Significant drug interactions exist with antihypertensive medications, anticoagulants, and antiplatelet agents such as warfarin and aspirin, as vincamine's vasodilatory and platelet-inhibiting effects can potentiate bleeding risk. Vincamine may also interact with drugs metabolized by CYP3A4 enzymes, potentially altering plasma concentrations. Periwinkle is contraindicated during pregnancy and breastfeeding due to insufficient safety data and the known cytotoxic alkaloid content present in the whole plant.